Navigation Links
ATS releases guidelines on the management of pulmonary hypertension of sickle cell disease
Date:3/14/2014

The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension.

"With the development of new treatments, many patients with sickle cell disease are now surviving long enough to develop pulmonary hypertension, with an estimated prevalence of 6 to 11 percent," said Elizabeth S. Klings, MD, associate professor of medicine at the Boston University School of Medicine and chair of the committee that produced the guidelines. "Although pulmonary hypertension and elevated tricuspid jet velocity (TRV, an indicator of pulmonary hypertension measured by echocardiography) are both associated with an increased mortality risk, there is currently no standardized approach for identifying and managing these patients."

The guidelines appear in the March 15th issue of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Guideline recommendations include:

  • Mortality risk can be accurately determined noninvasively by measurement of the TRV with Doppler echocardiography or by measurement of serum N-terminal probrain natriuretic peptide (NT-pro-BNP) levels and can be determined invasively by direct hemodynamic measurements via right heart catheterization (RHC).

  • An increased risk for mortality is defined as a TRV ≥ 2.5 m/second, an NT-pro-BNP level ≥ 160 pg/ml, or RHC-confirmed pulmonary hypertension.

  • Patients found to have an increased mortality risk should be treated with hydroxyurea. Patients who do not respond to or are not candidates for hydroxyurea treatment can be considered for chronic transfusion therapy.

  • In patients with RHC-confirmed pulmonary hypertension, venous thromboembolism, and no additional risk factors for hemorrhage, indefinite anticoagulant therapy rather than a limited duration of therapy should be used.

  • Patients with elevated TRV alone or elevated NT-pro-BNP alone should not be treated with targeted pulmonary arterial hypertension therapies, including prostanoid, endothelin receptor antagonist, and phosphodiesterase-5 inhibitor therapy

  • Most patients with RHC-confirmed pulmonary hypertension should not be treated with targeted therapy

  • In select patents with RHC-confirmed marked elevation of pulmonary vascular resistance, normal pulmonary capillary wedge pressure, and related symptoms, a trial of either a prostanoid or an endothelin receptor antagonist may be performed.

  • Patients with RHC-confirmed marked elevation of pulmonary vascular resistance, normal pulmonary capillary wedge pressure, and related symptoms should not receive phosphodiesterase-5 inhibitor therapy as first-line treatment.

"As our understanding of sickle cell disease develops, so will our ability to detect disease earlier and to tailor treatment approaches. We need to continue our research efforts into this disease and its management to understand what the optimal treatment regimen for these patients is. Most of our current recommendations are limited by a lack of large-scale clinical trials in this population." said Dr. Klings. "Management of patients with sickle cell disease with an increased risk for mortality and pulmonary hypertension will ultimately be a collaborative effort including adult and pediatric pulmonologists, cardiologists, and hematologists."


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Pro-Tek Chemical Releases Coupon Promotion
2. Expert San Diego Dermatologist Sabrina Fabi, MD Releases Video Demonstrating New Laser Treatment to Reduce Appearance of Brown Spots
3. Onnit Releases All-In-One Daily Greens Drink Mix
4. Narconon Releases Parents’ Tools to Effectively Communicate Marijuana Abuse Dangers
5. Pixel Film Studios Releases TransCurve 3D Curved Line Transitions for Final Cut Pro X
6. Norwalk, CT Chiropractor Releases Educational Website
7. Pixel Film Studios Releases White Board Info Graphics for Final Cut Pro X with ProGraph Volume 4
8. Merrill DataSite Releases New Comments: Majority of FDI Starting to Flow Into Emerging Markets
9. Sarantos Releases First Music Video - "Not Where I Wanna Be"
10. Advanced Kiosks Releases 2014’s Must-Have Marketing Tool
11. NCPDP Releases Its Top Four Goals for 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... today provides the latest information and contact points to easily connect elderly veterans ... care, assisted living, and elder-care funding. It also conveys material on this year's ...
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data ... has introduced an innovative workstation designed to reduce nursing fatigue while enhancing productivity. ... EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to the limitations of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network offers physicians ... controlled and non-controlled substances plus the ability to manage orders on their desktop ... now accept electronic prescriptions, according to the Office of the National Coordinator of ...
(Date:2/17/2017)... (PRWEB) , ... February 17, ... ... Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 — ... are the critical reimbursement questions manufacturers should be asking before selecting an ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 ... manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The methods ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... YORK , Feb. 20, 2017  This report analyzes the ... Million. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Read the full report: http://www.reportlinker.com/p04707127-summary/view-report.html ... period 2015 through 2022. Also, a six-year historic analysis is ...
(Date:2/20/2017)... 20, 2017  National Decision Support Company (NDSC) ... company,s CareSelect Imaging platform within the full range ... the technical foundation for MEDITECH sites, through a ... Clinical Decision Support Mechanism through the MEDITECH EHR. ... and support the integration of NDSC,s mechanism, which ...
(Date:2/20/2017)... Feb. 20, 2017   Orion Health ™ ... Amadeus precision medicine platform to the Amazon Web ... over 110 million patient records globally. "We ... big data solutions built on modern, scalable technology," said ... Life Sciences. "The AWS Cloud gives healthcare companies a ...
Breaking Medicine Technology: